A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations

Trial Profile

A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Danirixin (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms GSK1325756 FTIP COPD Study
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 23 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 11 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 11 Sep 2015 Planned End Date changed from 1 May 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top